Trial reportBritish journal of cancer2014
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.
Trial report in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Advancing immune checkpoint inhibitor rechallenge: key insights into efficacy, safety, and personalized strategies in advanced solid tumors.Frontiers in oncology · 2026Pooled it
- Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review.Frontiers in neurology · 2024Pooled it
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.BMC medicine · 2015Pooled it
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Trial
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Trial
- Review
- Checkpoint Inhibitors and Beyond: A Systematic Review of Immunotherapy in Cutaneous Malignancies.Cureus · 2025Review
- Immune checkpoint biology in hepatocellular carcinoma (Review).Oncology letters · 2025Review
- Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.British journal of cancer · 2025Article
- Efficacy and safety analysis of atezolizumab continuation beyond progression in extensive-stage small cell lung cancer.Clinical and experimental medicine · 2025Article
- Article
- The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge-A Systematic Review.Cancers · 2023Review
- Current Status in Rechallenge of Immunotherapy.International journal of biological sciences · 2023Review
- Review
- Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.Translational lung cancer research · 2022Article
- Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review.Cancers · 2022Review
- Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.Journal for immunotherapy of cancer · 2021Review
- Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.The Lancet. Respiratory medicine · 2021Article
- Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study.Current oncology (Toronto, Ont.) · 2021Observational
- Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma.Annals of hematology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetreatment with ipilimumab has been shown to re-establish disease control in some patients with disease progression. Here, we report the efficacy and safety of retreatment with ipilimumab 3 mg kg(-1) among patients participating in an expanded access programme in Italy.
methodsPatients who achieved disease control during induction therapy were retreated with ipilimumab upon progression (3 mg kg(-1) every 3 weeks for up to four doses), providing they had not experienced toxicity that precluded further dosing. Tumour assessments were conducted after retreatment, and patients were monitored throughout for adverse events.
resultsOf 855 patients treated with ipilimumab, 51 were retreated upon disease progression. Of these, 28 (55%) regained disease control upon retreatment and 42% were alive 2 years after the first induction dose of ipilimumab; median overall survival was 21 months. Eleven patients (22%) had a treatment-related adverse event of any grade during retreatment. These were generally mild-to-moderate and resolved within a median of 4 days. No new types of toxicity were reported.
conclusionsFor patients who meet predefined criteria, retreatment with ipilimumab is generally well tolerated and can translate into clinical benefit. This strategy should be compared with other therapeutic options in randomised controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.